IP Library Granted Patent US 11,918,628
Granted Patent B2
US 11,918,628 · App. 18/355,223 · Granted Mar 5, 2024

Controlled-release PTH compound

Inventors: Kennett Sprogøe (Holte, DK); Felix Cleemann (Mainz, DE); Guillaume Maitro (Mannheim, DE); Mathias Krusch (Hirschhorn, DE); Thomas Wegge (Heidelberg, DE); Joachim Zettler (Heidelberg, DE)
Assignee: ASCENDIS PHARMA BONE DISEASES A/S
A61K38/29A61K9/0019A61K9/1647A61K47/54A61K47/545A61K47/60A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,918,628
App. No.
18/355,223
Granted
Mar 5, 2024
Kind
B2
Abstract

The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.

Claims (20)

1. A parathyroid hormone (PTH) conjugate of formula:

or a pharmaceutically acceptable salt thereof, wherein

the unmarked dashed line indicates the attachment by an amide bond to the N-terminal nitrogen of a PTH moiety, the amino acid sequence of which consists of the sequence of SEQ ID NO:51; and the dashed line marked with the asterisk indicates attachment to a moiety

wherein

m and p are independently an integer ranging from and including 150 to 1000.

2. The PTH conjugate or pharmaceutically acceptable salt thereof of claim 1 , wherein the moiety

has a molecular weight of about 15-80 kDa.

3. The PTH conjugate or pharmaceutically acceptable salt thereof of claim 1 , wherein m and p are the same integer.

4. A pharmaceutical composition comprising the PTH conjugate or pharmaceutically acceptable salt thereof of claim 1 and at least one excipient.

5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition has a pH of 4-6.

6. A liquid pharmaceutical composition comprising

a parathyroid hormone (PTH) conjugate of formula:

or a pharmaceutically acceptable salt thereof, and a solvent, wherein

the unmarked dashed line indicates the attachment by an amide bond to the N-terminal nitrogen of a PTH moiety, the amino acid sequence of which consists of the sequence of SEQ ID NO:51; and the dashed line marked with the asterisk indicates attachment to a moiety

wherein

m and p are independently an integer ranging from and including 150 to 1000.

7. The liquid pharmaceutical composition of claim 6 , wherein the moiety

has a molecular weight of about 15-80 kDa.

8. The liquid pharmaceutical composition of claim 7 , wherein m and p are the same integer.

9. The liquid pharmaceutical composition of claim 7 , wherein the solvent is water.

Priority Claims (2)
EP 16191451 · Sep 29, 2016 · regional
EP 17155843 · Feb 13, 2017 · regional
Continuity (3)
Continuation 18063294 · Dec 8, 2022
Continuation 16337713
Related Publication 20230381284A1 · Nov 30, 2023
Cited By (4)
US 12,233,115 US 12,295,989 US 12,403,182 US 12,453,778